Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Breast

Triple Negative Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Phase 2/3 Active not recruiting

503 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00679029 2023-12-11

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase 2 Terminated

15 enrolled 9 charts

Breast

Breast Neoplasms

NCT06121570 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT00591851 2023-09-25

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Phase 2 Completed

70 enrolled 6 charts

Breast

Breast Neoplasms

NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Phase 2 Terminated

3 enrolled 6 charts

Breast

Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Phase 1 Completed

9 enrolled 17 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03329378 2023-08-22

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Phase 2 Terminated

7 enrolled 10 charts

Breast

Locally Advanced Breast Cancer

Clinical Trials

I-SPY

CARABELA

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

OTT15-04

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

NeoTRACT

NeoADAPT

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer

TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer

TIL; PD1; PDL1

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

DA-PET

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

BARBICAN

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

RESPONSE

met-HEReMYTA

SAFIR02_Breast

Vaccination of High Risk Breast Cancer Patients

Vaccination of Triple Negative Breast Cancer Patients

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

QUEEN-Neo

COC-IDCB

KEYPARTNER

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

APTneo

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer